XERODERMA PIGMENTOSUM: LIVING IN THE DARK BUT WITH HOPE IN THERAPY


Autoria(s): LIMA-BESSA, K. M.; SOLTYS, D. T.; MARCHETTO, M. C.; MENCK, C. F. Martins
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2009

Resumo

Xeroderma pigmentosum patients suffer from extreme photosensitivity caused by a genetic defect in DNA repair pathways. This condition obliges them to live in darkness and avoid sunshine. Although the molecular basis of the defect has been known for more than 40 years now, the treatment possibilities are very limited, and to date all have been focused on the skin. Herein, we summarize the effects of sunlight and the molecular mechanisms implicated in the defects that lead to this syndrome, as well as the strategies that have been tested to alleviate skin manifestations, including cancer. Preclinical attempts to correct genetic defects by means of different gene therapy approaches are also described. All these efforts are now bringing hope and some light into the life of patients and their families.

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

FAPESP (Sao Paulo, Brazil)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

CNPq (Brasilia, Brazil)

Identificador

DRUGS OF THE FUTURE, v.34, n.8, p.665-672, 2009

0377-8282

http://producao.usp.br/handle/BDPI/28452

10.1358/dof.2009.34.8.1394556

http://dx.doi.org/10.1358/dof.2009.34.8.1394556

Idioma(s)

eng

Publicador

PROUS SCIENCE, SA-THOMSON REUTERS

Relação

Drugs of the Future

Direitos

closedAccess

Copyright PROUS SCIENCE, SA-THOMSON REUTERS

Palavras-Chave #PLURIPOTENT STEM-CELLS #IMIQUIMOD 5-PERCENT CREAM #I/II CLINICAL-EVALUATION #MEDIATED GENE-TRANSFER #HUMAN SKIN SUBSTITUTE #DNA-POLYMERASE-ETA #GROUP-C #RECOMBINANT ADENOVIRUS #GROUP-A #LENTIVIRAL VECTORS #Pharmacology & Pharmacy
Tipo

article

original article

publishedVersion